Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 140,225
  • Shares Outstanding, K 1,219,347
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,840 K
  • EBIT $ 9 M
  • EBITDA $ 11 M
  • 60-Month Beta 0.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.02 on 10/15/24
  • Next Earnings Date 01/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1031 +12.32%
on 11/29/24
0.1500 -22.80%
on 12/13/24
-0.0016 (-1.36%)
since 11/26/24
3-Month
0.1031 +12.32%
on 11/29/24
0.1650 -29.82%
on 09/27/24
-0.0426 (-26.89%)
since 09/26/24
52-Week
0.1031 +12.32%
on 11/29/24
0.3150 -63.24%
on 05/29/24
-0.0717 (-38.24%)
since 12/26/23

Most Recent Stories

More News
December 2024 Letter to Shareholders

CYDY : 0.1158 (+0.70%)
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

CYDY : 0.1158 (+0.70%)
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

CYDY : 0.1158 (+0.70%)
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories

CYDY : 0.1158 (+0.70%)
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development

CYDY : 0.1158 (+0.70%)
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques

CYDY : 0.1158 (+0.70%)
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

CYDY : 0.1158 (+0.70%)
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf...

CYDY : 0.1158 (+0.70%)
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf...

CYDY : 0.1158 (+0.70%)
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...

CYDY : 0.1158 (+0.70%)

Business Summary

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has...

See More

Key Turning Points

3rd Resistance Point 0.1240
2nd Resistance Point 0.1221
1st Resistance Point 0.1189
Last Price 0.1158
1st Support Level 0.1138
2nd Support Level 0.1119
3rd Support Level 0.1087

See More

52-Week High 0.3150
Fibonacci 61.8% 0.2341
Fibonacci 50% 0.2090
Fibonacci 38.2% 0.1840
Last Price 0.1158
52-Week Low 0.1031

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar